Grifols’ ADRs are trading higher in the U.S. as the market continues to price in a potential balance-sheet reset tied to its plan to float up to 20% of its U.S. Biopharma business—an equity raise that has been framed as potentially as large as €4.3 billion. That prospective cash infusion is viewed as a lever to accelerate debt reduction and improve financial flexibility, which has been a central investor focus since the company’s leverage became a key overhang.

Sentiment has also been supported by improving credit optics. Moody’s upgraded Grifols’ probability of default rating to B1-PD from B2-PD, reinforcing the narrative that credit risk is easing. Separately, Grifols has been working on expanding liquidity via a significantly larger revolving credit facility (about $2 billion), contingent on completing its Term Loan B refinancing by May 31, 2026—another milestone investors are watching for signs that funding costs and maturities can be better managed.

Near-term, traders are likely to focus on (1) whether Grifols provides more concrete timing and structure details on the U.S. Biopharma listing, (2) whether the company executes the Term Loan B refinancing by the May 31, 2026 target, and (3) any additional credit-rating actions that could lower borrowing costs further. The next major scheduled catalyst for fundamentals is the company’s next earnings report date, which market calendars currently flag for late April 2026.